Immune-mediated inflammatory disease therapeutics: past, present and future

• Published in: Nature reviews. Immunology Vol. 21; no. 10; pp. 680 - 686
• Main Authors: McInnes, Iain B., Gravallese, Ellen M.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01-10-2021; Nature Publishing Group
• Subjects: 631/250/251; 631/250/38; Animals; Antibodies, Monoclonal - therapeutic use; Biological products; Biomedical and Life Sciences; Biomedicine; Biotechnology; Drug therapy; Forecasts and trends; Humans; Immunologic diseases; Immunology; Immunomodulation; Inflammation; Inflammation - drug therapy; Inflammation - immunology; Inflammation - therapy; Inflammatory diseases; Molecular Targeted Therapy - trends; Monoclonal antibodies; Perspective; United Kingdom
• ISSN: 1474-1733; 1474-1741
• DOI: 10.1038/s41577-021-00603-1

Immune-mediated inflammatory diseases are common and clinically diverse. Although they are currently incurable, the therapeutic armamentarium for immune-mediated inflammatory diseases has been transformed in the past two decades. We have moved from the wide application of broad-spectrum immune modulators to the routine use of agents with exquisite specificity, arising from monoclonal and molecular biotechnology and more recently from highly targeted medicinal chemistry. Here we describe key advances and lessons that drove this remarkable progress and thereafter reflect on the next steps in this ongoing journey.
In this Perspective, McInnes and Gravallese highlight the remarkable progress made over the past 20 years in treating immune-mediated inflammatory diseases. The available therapies have progressed from broad-spectrum immune modulators to highly targeted biological and small-molecule agents as our understanding of disease mechanisms has advanced.